Aldara®-induced skin inflammation: Studies of patients with psoriasis

British Journal of Dermatology

Volumn 172, Issue 2, 2015, Pages 345-353

  Vinter, H ^a   Iversen, L ^a   Steiniche, T ^a   Kragballe, K ^a   Johansen, C ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23P19; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; OINTMENT;

ACANTHOSIS; ADAPTIVE IMMUNITY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DERMATITIS; EROSION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MALE; OCCLUSION; PARAKERATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS LIKE SKIN INFLAMMATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN INDURATION; SKIN REDNESS; ADMINISTRATION AND DOSAGE; CHEMICALLY INDUCED; DRUG ERUPTIONS; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; OINTMENT; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS;

EID: 84922791571     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13236     Document Type: Article

References (47)

1. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
2. Nograles KE, Davidovici B, Krueger JG,. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010; 29: 3-9.
3. Rongioletti F, Fiorucci C, Parodi A,. Psoriasis induced or aggravated by drugs. J Rheumatol Suppl 2009; 83: 59-61.
4. Fanti PA, Dika E, Vaccari S, et al,. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-5.
5. Gilliet M, Conrad C, Geiges M, et al,. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-5.
6. Rajan N, Langtry JA,. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31: 140-1.
7. Wu JK, Siller G, Strutton G,. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004; 45: 47-50.
8. Patel U, Mark NM, Machler BC, Levine VJ,. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011; 164: 670-2.
9. Schon MP, Schon M,. Imiquimod: mode of action. Br J Dermatol 2007; 157 (Suppl. 2): 8-13.
10. Miller RL, Gerster JF, Owens ML, et al,. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21: 1-14.
11. Urosevic M, Dummer R, Conrad C, et al,. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97: 1143-53.
12. Walter A, Schafer M, Cecconi V, et al,. Aldara activates TLR7-independent immune defence. Nat Commun 2013; 4: 1560.
13. Zaba LC, Krueger JG, Lowes MA,. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009; 129: 302-8.
14. Cella M, Jarrossay D, Facchetti F, et al,. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5: 919-23.
15. Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43.
16. Palamara F, Meindl S, Holcmann M, et al,. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173: 3051-61.
17. van der Fits L, Mourits S, Voerman JS, et al,. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836-45.
18. Van Belle AB, de Heusch M, Lemaire MM, et al,. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 2012; 188: 462-9.
19. Ramirez-Carrozzi V, Sambandam A, Luis E, et al,. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011; 12: 1159-66.
20. Lee E, Trepicchio WL, Oestreicher JL, et al,. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
21. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al,. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-11.
22. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
23. Blauvelt A,. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-7.
24. Boniface K, Guignouard E, Pedretti N, et al,. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-15.
25. Johansen C, Vinter H, Soegaard-Madsen L, et al,. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Br J Dermatol 2010; 163: 1194-204.
26. Schon MP,. Animal models of psoriasis-what can we learn from them? J Invest Dermatol 1999; 112: 405-10.
27. Gudjonsson JE, Johnston A, Dyson M, et al,. Mouse models of psoriasis. J Invest Dermatol 2007; 127: 1292-308.
28. Conrad C, Nestle FO,. Animal models of psoriasis and psoriatic arthritis: an update. Curr Rheumatol Rep 2006; 8: 342-7.
29. Swindell WR, Johnston A, Carbajal S, et al,. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 2011; 6: e18266.
30. Helwig EB,. Pathology of psoriasis. Ann N Y Acad Sci 1958; 73: 924-35.
31. Wohn C, Ober-Blobaum JL, Haak S, et al,. Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci USA 2013; 110: 10723-8.
32. Pantelyushin S, Haak S, Ingold B, et al,. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012; 122: 2252-6.
33. El Malki K, Karbach SH, Huppert J, et al,. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol 2013; 133: 441-51.
34. Hoste E, Denecker G, Gilbert B, et al,. Caspase-14-deficient mice are more prone to the development of parakeratosis. J Invest Dermatol 2013; 133: 742-50.
35. Uribe-Herranz M, Lian LH, Hooper KM, et al,. IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation. J Invest Dermatol 2013; 133: 1541-9.
36. Wollenberg A, Wagner M, Günther S, et al,. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-102.
37. Kawai T, Sato S, Ishii KJ, et al,. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004; 5: 1061-8.
38. Stanley MA,. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
39. Johansen C, Riis JL, Gedebjerg A, et al,. Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κB. J Biol Chem 2011; 286: 25487-94.
40. Sabat R, Wolk K,. Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. J Dtsch Dermatol Ges 2011; 9: 518-23.
41. Otkjaer K, Kragballe K, Funding AT, et al,. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005; 153: 911-18.
42. Duhen T, Geiger R, Jarrossay D, et al,. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10: 857-63.
43. Kunz S, Wolk K, Witte E, et al,. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006; 15: 991-1004.
44. Di Meglio P, Perera GK, Nestle FO,. The multitasking organ: recent insights into skin immune function. Immunity 2011; 35: 857-69.
45. Chu CC, Ali N, Karagiannis P, et al,. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 2012; 209: 935-45.
46. Sugiyama H, Gyulai R, Toichi E, et al,. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174: 164-73.
47. Eyerich S, Onken AT, Weidinger S, et al,. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365: 231-8.